09:01 AM EDT, 08/05/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) reported a Q2 net loss Tuesday of $1 per share, narrowing from a loss of $1.11 a year earlier.

Analysts polled by FactSet expected a loss of $1.11.

License and collaboration revenue for the quarter ended June 30 was $8.5 million, down from $11.8 million a year earlier.

Analysts surveyed by FactSet expected $12.8 million.

The biotechnology company said it had cash, cash equivalents and marketable securities of $1.15 billion as of June 30 to finance its expected operating expenses and capital expenditure requirements into 2028.